ABOSEarnings•globenewswire•
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
Sentiment:Negative (30)
Summary
NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the second quarter of 2025 and provided a business update.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire